Fibroblast growth factor 23 and adverse clinical outcomes in chronic kidney disease
T Isakova - Current opinion in nephrology and hypertension, 2012 - journals.lww.com
Current opinion in nephrology and hypertension, 2012•journals.lww.com
Fibroblast growth factor 23 and adverse clinical outcomes in... : Current Opinion in Nephrology
and Hypertension Fibroblast growth factor 23 and adverse clinical outcomes in chronic kidney
disease : Current Opinion in Nephrology and Hypertension Log in or Register Subscribe to
journalSubscribe Get new issue alertsGet alerts Secondary Logo Journal Logo Advanced
Search Toggle navigation Subscribe Register Login Articles & Issues Videos For Authors
Journal Info Advanced Search May 2012 - Volume 21 - Issue 3 Previous Article Next Article …
and Hypertension Fibroblast growth factor 23 and adverse clinical outcomes in chronic kidney
disease : Current Opinion in Nephrology and Hypertension Log in or Register Subscribe to
journalSubscribe Get new issue alertsGet alerts Secondary Logo Journal Logo Advanced
Search Toggle navigation Subscribe Register Login Articles & Issues Videos For Authors
Journal Info Advanced Search May 2012 - Volume 21 - Issue 3 Previous Article Next Article …
Summary
FGF23 is emerging as a novel risk factor in CKD. Future studies should determine whether interventions that lower FGF23 levels improve clinical outcomes in CKD.
Lippincott Williams & Wilkins